# A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of DGX-001

> **NCT05121831** · PHASE1 · COMPLETED · sponsor: **Digestome Therapeutics** · enrollment: 68 (actual)

## Conditions studied

- Depressive Disorder

## Interventions

- **DRUG:** DGX-001Dose 1
- **DRUG:** DGX-001 Dose 2
- **DRUG:** DGX-001 Dose 3
- **DRUG:** DGX-001 Dose 4
- **DRUG:** MAD dose panel of DGX-001

## Key facts

- **NCT ID:** NCT05121831
- **Lead sponsor:** Digestome Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-24
- **Primary completion:** 2022-11-06
- **Final completion:** 2022-11-06
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05121831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05121831, "A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of DGX-001". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05121831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*